曲妥珠单抗
医学
癌症
免疫系统
癌症研究
抗药性
免疫逃逸
疾病
后天抵抗
单克隆抗体
单克隆
临床试验
胃食管交界处
肿瘤科
免疫疗法
肿瘤微环境
内科学
表皮生长因子受体
癌细胞
免疫学
作者
Huifang Lv,Wanying Zhao,Saiqi Wang,Yunduan He,Caiyun Nie,Xiaobing Chen
出处
期刊:
[Oxford University Press]
日期:2026-01-20
卷期号:14: goag068-goag068
标识
DOI:10.1093/gastro/goag068
摘要
The combination of trastuzumab and chemotherapy, with or without pembrolizumab, is the current first-line standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer and gastroesophageal junction cancer. However, upon disease progression, subsequent therapies often yield limited clinical benefit. The mechanisms of drug resistance to trastuzumab remain unresolved. Current studies on its resistance mechanisms have largely focused on alterations in the HER2 pathway, including HER2 heterogeneity, reduced or absent HER2 expression, variations in HER2 dimerization, and mutations in downstream components, among others. Crucially, as a monoclonal antibody, the antitumor activity of trastuzumab is partially mediated by the immune system, yet the immunology-related mechanisms of resistance are frequently overlooked. In this review, we systematically analyse the outcomes of both successful and failed clinical trials of anti-HER2 agents to propose that immune escape within the tumor microenvironment is a key driver of trastuzumab resistance in HER2-positive gastric cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI